Bulletin of the World Health Organization

Estimating the costs of achieving the WHO–UNICEF Global Immunization Vision and Strategy, 2006–2015

Lara J Wolfson, François Gasse, Shook-Pui Lee-Martin, Patrick Lydon, Ahmed Magan, Abdelmajid Tibouti, Benjamin Johns, Raymond Hutubessy, Peter Salama, Jean-Marie Okwo-Bele

Volume 86, Number 1, January 2008, 27-39

Table 2. Vaccine cost assumptions, 2005–2015

Vaccine Average dosesper course Number of doses per vial Packed cubic volume per dose(ml) Actual weighted average price in 2005 per dose (US$) Projected price in 2010 per dose (US$) Projected price in 2015 per dose (US$) % of vaccine price charged for freight Average vaccinewastagerate (%)
Routine
Baccillus Calmette-Guérin (BCG) 1 20 1 0.09 0.11 0.13 0.7 50
Diphtheria-tetanus-pertussis (DTP) 3 10 3 0.14 0.35 0.45 1.5 25
Measles (MCV) 1 or 2 10 3 0.17 0.22 0.29 2.0 40
Oral polio (OPV) 3 or 4 10 2.5 0.11 0.16 1.1 30
Tetanus toxoid (TT) 2 10 3 0.07 0.08 0.92 1.2 25
Underused
DTP-Hib 3 1 32.3 2.38 1.53 1.14 4.8 15
DTP-HepB 3 10 3 1.27 1.02 0.78 2.5 25
DTP-HepB-Hib 3 1 19.4 3.65 2.56 1.92 5.5 10
Hepatitis B (HepB) 3 or 4 10 2.9 0.27 0.30 0.35 2.7 25
Haemophilus influenzae type b (Hib) 3 2 4.8 2.38 1.53 1.14 9.5 15
Measles rubella (MR 1 or 2 10 3 0.49 0.71 0.92 7.3 40
Yellow fever (YF) 1 10 2.45 0.80 0.65 0.07 2.4 40
New
Meningococcal conjugate 1 10 2.5 0.44 0.58 3.7 25
Japanese encephalitis (JE) 1 1 60 3.02 2.96 4.5 25
Pneumococcal conjugate 3 1 40 5.00 4.00 2.5 5
Rotavirus 3 1 11.5 5.75 1.88 6.0 5
Campaigns
Measles 1 20 3 0.17 0.17 0.22 2.0 20
Meningococcal 1 6 2.5 0.37 0.44 0.58 3.7 15
TT 3 20 3 0.05 0.06 0.10 1.0 20
YF 1 10 2.45 0.06 0.07 0.77 0.2 15
[an error occurred while processing this directive]